Current Report Filing (8-k)
August 25 2017 - 5:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (date of Earliest Event Reported): August 23, 2017
moleculin
biotech, INC.
(Exact Name of Registrant as Specified in
its Charter)
DELAWARE
|
001-37758
|
47-4671997
|
(Sate or Other Jurisdiction of
Incorporation or Organization)
|
(Commission File No.)
|
(I.R.S. Employer Identification No.)
|
2575
WEST BELLFORT, SUITE 333, HOUSTON TX 77054
(Address of principal executive offices
and zip code)
(713) 300-5160
(Registrant’s telephone number, including
area code)
(Former name or former address, if changed
from last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(
see
General Instruction A.2. below):
¨
Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
x
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
x
|
Item 5.02
|
Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On August 23, 2017,
the Board of Directors of Moleculin Biotech, Inc. (the “Company”) approved a reorganization pursuant to which Dr. Donald
Picker has been appointed as chief scientific officer of the Company. Dr. Picker will no longer serve as president or chief operating
officer of the Company. Effective August 23, 2017, Mr. Walter Klemp, the Company’s chief executive officer, has been appointed
to serve as president of the Company. The foregoing reorganization will not change the amount of time either Dr. Picker or Mr.
Klemp will spend on Company matters, or modify their compensation arrangements.
Mr. Klemp, age 58,
is a co-founder of the Company, and has served as the Company’s chairman of the board and chief executive officer since July
2015. From 2006 until May 2016, Mr. Klemp served as the chairman, co-founder and part-time chief executive officer of Moleculin,
LLC. Mr. Klemp was also an equity holder in Moleculin, LLC at the time of the Company’s merger with Moleculin, LLC, and,
accordingly, received shares of Company common stock in the merger. Since November 2011, Mr. Klemp has also served as chief executive
officer of Soliton, Inc., a medical device company focused on developing new technology for use in aesthetics. Mr. Klemp served
as president and chief executive officer of Zeno Corporation from 2004 to April 2011, where he developed and marketed dermatology
devices and drugs from concept through FDA approval and market launch. From 1987 to 2000, Mr. Klemp served as chief executive officer
and chairman of Drypers Corporation, a publicly traded multinational consumer products company. Mr. Klemp controls AnnaMed, Inc.
In August 2015, in exchange for the issuance of 1,431,000 shares of common stock, the Company acquired the rights to the Annamycin
data related to the original Annamycin IND and the development of Annamycin.
SIGNATURE
Pursuant to the requirements
of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
MOLECULIN BIOTECH, INC.
|
|
Date: August 25, 2017
|
|
|
|
|
|
|
|
|
By:
|
/s/ Jonathan Foster
|
|
|
|
Jonathan Foster
|
|
|
|
Chief Financial Officer
|
|
Moleculin Biotech (NASDAQ:MBRX)
Historical Stock Chart
From Apr 2024 to May 2024
Moleculin Biotech (NASDAQ:MBRX)
Historical Stock Chart
From May 2023 to May 2024